Publications by authors named "William Heyward"

Claim this Profile
I
Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.
Sam Jackson, Joseph Lentino, James Kopp, Linda Murray, William Ellison, William L Heyward

Vaccine· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age.
Julia M Janssen, Sam Jackson, William L Heyward, Robert S Janssen

Vaccine· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus.
Julia M Janssen, William L Heyward, J Tyler Martin, Robert S Janssen

Vaccine· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.
William L Heyward, Michael Kyle, Joseph Blumenau, Matthew Davis, Keith Reisinger

Vaccine· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
Robert S Janssen, Roberto Mangoo-Karim, Pablo E Pergola, Matthias Girndt, Hamid Namini, William L Heyward

Vaccine· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.
Renee Kim Kuan, Robert Janssen, William Heyward, Sean Bennett, Robert Nordyke

Vaccine· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine.
Scott A Halperin, Brian J Ward, Marc Dionne, Joanne M Langley, Shelly A McNeil, William L Heyward

Hum Vaccin Immunother· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults.
Scott A Halperin, Shelly McNeil, Joanne M Langley, Bruce Smith, Donna MacKinnon-Cameron, William L Heyward

Vaccine· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
Scott A Halperin, Brian Ward, Curtis Cooper, Gerald Predy, Francisco Diaz-Mitoma, William L Heyward

Vaccine· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine.
Benjamin P Sablan, Dong Joon Kim, Nina G Barzaga, Wan Cheng Chow, Mong Cho, William L Heyward

Vaccine· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Social harms in injecting drug users participating in the first phase III HIV vaccine trial in Thailand.
Punnee Pitisuttithum, Kachit Choopanya, Valai Bussaratid, Suphak Vanichseni, Frits van Griensven, William Heyward

J Med Assoc Thai· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The future of HIV prevention: prospects for an effective anti-HIV microbicide.
Jeremy Nuttall, Joseph Romano, Karen Douville, Caroline Galbreath, Annaléne Nel, William Heyward

Infect Dis Clin North Am· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
Punnee Pitisuttithum, Peter Gilbert, Marc Gurwith, William Heyward, Michael Martin

J Infect Dis· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microbicides for the prevention of HIV infection in women: an overview of recent trials.
Zeda F Rosenberg, Annalene Nel, William Heyward, Mark Mitchnick

Curr Opin HIV AIDS· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.
Peter B Gilbert, Marta L Ackers, Phillip W Berman, Donald P Francis, Vladimir Popovic, William L Heyward

J Infect Dis· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.
Peter B Gilbert, Michael L Peterson, Dean Follmann, Michael G Hudgens, Donald P Francis, William L Heyward

J Infect Dis· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand.
Chitraporn Karnasuta, Robert M Paris, Josephine H Cox, Sorachai Nitayaphan, Punnee Pitisuttithum, William L Heyward

Vaccine· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1.
Punnee Pitisuttithum, Phillip W Berman, Benjaluck Phonrat, Pravan Suntharasamai, Suwanee Raktham, William L Heyward

J Acquir Immune Defic Syndr· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.
Sorachai Nitayaphan, Punnee Pitisuttithum, Chitraporn Karnasuta, Chirapa Eamsila, Mark de Souza, William Heyward

J Infect Dis· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX B/E HIV vaccine trial, Bangkok, Thailand.
Suphak Vanichseni, Jordan W Tappero, Punnee Pitisuttithum, Dwip Kitayaporn, Timothy D Mastro, William L Heyward

AIDS· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials.
Donald P Francis, William L Heyward, Vladimir Popovic, Patti Orozco-Cronin, Karin Orelind

AIDS· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incarceration and risk for HIV infection among injection drug users in Bangkok.
Kachit Choopanya, Don C Des Jarlais, Suphak Vanichseni, Dwip Kitayaporn, Philip A Mock, William L Heyward

J Acquir Immune Defic Syndr· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis